27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Genome-wide association studies have discovered numerous genomic loci associated with Alzheimer's disease (AD); yet the causal genes and variants are incompletely identified. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Pooled evidence from available trials reporting both reduction in amyloid levels and change in cognition suggests that amyloid reduction strategies do not substantially improve cognition. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Based on integrated review of laboratory, electrocardiogram, adverse events, and MRI, AAB-003 was safe and well tolerated up to 8 mg/kg for up to 91 weeks (FIH and extension trials) in patients with mild to moderate AD. 4 key findings →
Design: open-label trial Participants: 52 Evidence: high
Full summary, score breakdown and related studies → Original source
These findings support the short-term efficacy and safety of Lecanemab in early AD and highlight plasma biomarkers as a treatment-responsive biomarker. 3 key findings →
Design: cohort study Participants: 68 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Treatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes. 2 key findings →
Participants: 15,820 Evidence: high
Full summary, score breakdown and related studies → Original source
This study provides evidence that the effects of GLP-1 receptor agonists may extend beyond their known metabolic and cardioprotective benefits to include neuroprotection, associated with a decreased risk of developing various neurodegenerative disorders. 5 key findings →
Design: cohort study Participants: 102,935 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study evaluated the efficacy and safety of donepezil in patients with mild to moderately severe Alzheimer's disease, and examined the relationships between plasma donepezil concentration, red blood cell acetylcholinesterase (AChE) activity and clinical response. 5 key findings →
Participants: 161 Evidence: high
Full summary, score breakdown and related studies → Original source
No evidence of efficacy of 2 mg or 8 mg RSG XR monotherapy in cognition or global function was detected in the APOE-ε4-negative or other analysis populations. 2 key findings →
Design: open-label trial Participants: 693 Evidence: high
Full summary, score breakdown and related studies → Original source
Treatment with ChEIs results in a modest but significant therapeutic effect and modestly but significantly higher rates of adverse events and discontinuation of treatment. 2 key findings →
Design: meta-analysis Participants: 5,159 Evidence: high
Full summary, score breakdown and related studies → Original source
The target dose of 10 cm2 rivastigmine patch provides efficacy similar to the highest doses of capsules with a superior tolerability profile. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
In this 12-week trial, donepezil was not more effective than placebo in treating agitation in patients with Alzheimer's disease. 3 key findings →
Participants: 272 Evidence: low
Full summary, score breakdown and related studies → Original source
A long-term CMI in ChEI-treated early Alzheimer disease patients produced additional mood and cognitive benefits. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Diabetes and hyperinsulinemia may be risk factors for Alzheimer's disease (AD). 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
The disclosure of APOE genotyping results to adult children of patients with Alzheimer's disease did not result in significant short-term psychological risks. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
The beneficial effect of DBS on motor function was stable and comparable by target over 36 months. 3 key findings →
Design: randomized controlled trial Participants: 89 Evidence: high
Full summary, score breakdown and related studies → Original source
Overall, we found that probiotic and selenium co-supplementation for 12 weeks to patients with AD improved cognitive function and some metabolic profiles. 5 key findings →
Participants: 27 Evidence: high
Full summary, score breakdown and related studies → Original source
Exercise training increases fitness, physical function, cognitive function, and positive behavior in people with dementia and related cognitive impairments. 3 key findings →
Design: meta-analysis Participants: 2,020 Evidence: high
Full summary, score breakdown and related studies → Original source
There is very limited evidence that exercise improves cognitive function in individuals with MCI, although published research is of moderate quality and inconclusive due to low statistical power. 5 key findings →
Design: meta-analysis Participants: 1,695 Evidence: high
Full summary, score breakdown and related studies → Original source
Impaired odor identification, particularly in the anosmic range, is associated with increased mortality in older adults even after controlling for dementia and medical comorbidity. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Consistent with previous reports, risk factors and prodromal features associated with PD included traumatic brain injury, odds ratio (OR), 1.62; 95% CI, 1.36-1.92; alcohol misuse, OR, 1.32; 95% CI, 1.21-1.44; hypertension, OR, 1.29; 95% CI, 1.26-1.31; anosmia, OR, 2.16; 95% CI, 1.59-2.93; and parasomnias (including RBD), OR, 1.62; 95% CI, 1.42-1.84. 4 key findings →
Design: cohort study Participants: 345 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Topic Visual impairment (VI) and cognitive impairment (CIM) are prevalent age-related conditions that impose substantial burden on the society. 5 key findings →
Design: systematic review Participants: 47 Evidence: high
Full summary, score breakdown and related studies → Original source
In this study, hearing loss was positively associated with a risk of dementia, especially in patients aged 45 to 64 years. 5 key findings →
Design: cohort study Participants: 8,135 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Despite increased use of analgesics, pain is still prevalent in people with dementia. 1 key finding →
Design: systematic review Participants: 12 Evidence: high
Full summary, score breakdown and related studies → Original source
The estimated costs of dementia in LMICs are lower than in high-income countries. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Randomized control intervention. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →